Advertisement

Topics

Memorial Sloan Kettering Cancer Center Company Profile

20:23 EST 12th December 2018 | BioPortfolio

The CMO’s Structure, Assets, and Goals


News Articles [2954 Associated News Articles listed on BioPortfolio]

Sloan Kettering’s Widening Institutional Reckoning Over Ethics Crisis Snags Center’s Top Executive

Memorial Sloan Kettering Cancer Center President, Dr. Craig Thompson, announced that he will resign from the boards of Merck and Charles River Laboratories. Merck is the maker of the blockbuster cance...

Sloan Kettering VP Has To Hand Over $1.4M Windfall From Biotech Company In Center’s Effort To Contain Ethics Crisis

The Memorial Sloan Kettering Cancer Center has come under the microscope for potential breaches regarding financial conflicts-of-interest. On Friday, the Manhattan-based cancer center issued a memo to...

Memorial Sloan Kettering CMO Steps Down Following His Failure to Disclose Financial Ties to the I...

Days after a report by The New York Times and ProPublica revealed José Baselga, chief medical officer at Memorial Sloan Kettering Cancer Center, failed to disclose his vast financial ties to various ...

Sloan Kettering CEO leaves Merck board after scandal

The chief executive of Memorial Sloan Kettering Cancer Center, Craig Thompson, resigned from Merck’s board of directors, following media investigations about the center’s ties to the pharma indust...

SHYFT, The Memorial Sloan Kettering Cancer Center, Pure Storage, And More: News From November 2018

Clinical Informatics News | November was full of exciting news in the clinical trial and healthcare community, including partnerships, products, and promotions from SHYFT, the Memorial Sloan Kett...

Memorial Sloan Kettering Cancer Center Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 30032018] Prices from USD $350

Memorial Sloan Kettering Cancer Center Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Memorial Sloan Kettering Cancer Center Mergers Acquisitions MA, Part...

Memorial Sloan Kettering Cancer Center Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 23042018] Prices from USD $350

Memorial Sloan Kettering Cancer Center Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Memorial Sloan Kettering Cancer Center Mergers Acquisitions MA, Part...

Memorial Sloan Kettering Cancer Center Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 28072018] Prices from USD $350

Memorial Sloan Kettering Cancer Center Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Memorial Sloan Kettering Cancer Center Mergers Acquisitions MA, Part...

PubMed Articles [6677 Associated PubMed Articles listed on BioPortfolio]

Multiparametric magnetic resonance imaging versus Partin tables and the Memorial Sloan-Kettering cancer center nomogram in risk stratification of patients with prostate cancer referred to external beam radiation therapy.

To evaluate the agreement between multiparametric Magnetic Resonance Imaging (mpMRI), Partin tables (PT) and the Memorial Sloan Kettering Cancer Center nomogram (MSKCCn) in assessing risk category in ...

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.

Purpose Treatment with programmed cell death-1 or programmed death ligand 1 (PD-(L)1) inhibitors is now standard therapy for patients with lung cancer. The immunosuppressive effect of corticosteroids ...

Has the Age of Cytoreductive Nephrectomy come to an end?

The CARMENA (Cancer du Rein Metastatique Nephrectomie et Antiangiogéniques) trial was a prospective, multicentre, open-label, phase 3 trial that randomly assigned patients with Memorial Sloan Ketteri...

Ameloblastomas of the mandible and maxilla.

Ameloblastoma is a histologically benign but locally aggressive tumor of the jaws. We conducted a retrospective cohort study to review the clinical, radiologic, and pathologic features of patients wit...

Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population.

Purpose Sunitinib and pazopanib are multitargeted tyrosine kinase inhibitors (TKIs) that act against vascular endothelial growth factor receptors and are standard first-line treatment options for meta...

Clinical Trials [10980 Associated Clinical Trials listed on BioPortfolio]

Measurement of Cancer-Related Risk Perception in Smokers

The purpose of this study is to develop an accurate way of measuring people's thoughts about cancer risk. The researchers at the Queens Hospital Center, Memorial Sloan-Kettering Cancer Cen...

Collection of Tissue, Blood, and Cells to Be Used For Studying the Causes, Prevention, Diagnosis, and Treatment of Breast Cancer

The purpose of this study is to collect a blood sample from patients with breast disease (cases) and from individuals without breast cancer (controls)that may be used for research purposes...

Acute Normovolemic Hemodilution Versus Standard Intraoperative Management in Patients Having Hepatic Resection and Pancreaticoduodenectomy

With a major liver or pancreas operation, there is a chance that one will require a transfusion of blood products (either red blood cells or plasma). This may be necessary during the oper...

A Randomized Study of Sulindac in Oral Premalignant Lesions

The purpose of this study is to see if a drug called sulindac can prevent the development of changes in the mouth that are related to oral pre-cancer growths (oral epithelial dysplasia) or...

Older Breast Cancer Patients: Risk for Cognitive Decline

The goal of this study is to evaluate the impact of systemic therapy on cognition in older breast cancer patients, explore which domains are most affected, measure associations between cog...

Companies [2867 Associated Companies listed on BioPortfolio]

Memorial Sloan-Kettering Cancer Center

Memorial Sloan-Kettering Cancer Center's tradition of care began more than 100 years ago. In 1884, the cornerstone of the New York Cancer Hospital -- what was later to become Memorial Hospital for Can...

The Society of Memorial Sloan-Kettering Cancer Center

Memorial Sloan Kettering Cancer Center

The CMO’s Structure, Assets, and Goals

Optimer Pharmaceuticals

Optimer's core competence includes the development of innovative drugs for treating diseases that currently have no satisfactory therapy. These include antibiotics for drug-resistant bacterial infecti...

Mojave Therapeutics Incorporated

Mojave Therapeutics is building a new class of biopharmaceuticals that primes the immune system to fight cancer and viral diseases. Mojave’s core technologies, developed by leading researchers at Me...

More Information about "Memorial Sloan Kettering Cancer Center" on BioPortfolio

We have published hundreds of Memorial Sloan Kettering Cancer Center news stories on BioPortfolio along with dozens of Memorial Sloan Kettering Cancer Center Clinical Trials and PubMed Articles about Memorial Sloan Kettering Cancer Center for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Memorial Sloan Kettering Cancer Center Companies in our database. You can also find out about relevant Memorial Sloan Kettering Cancer Center Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record